Endocrine Abstracts

Although non-alcoholic fatty liver disease (NAFLD) patients are rapidly growing, there is not optimal therapy to improve NAFLD. NAFLD is strongly associated with insulin resistance. The peroxisome proliferator-activated receptor (PPAR) activator thiazolidinediones (TZD) is an insulin sensitizer, and have been focused as the drug for NAFLD. However, the TZD remain debate as drug of choice on NAFLD because of its conflicting results on the hepatic steatosis and fibrosis. Lobegli...